# Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

> **NCT00081770** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 4469 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **BIOLOGICAL:** PegIntron (peginterferon alfa-2b; SCH 54031)
- **BIOLOGICAL:** PegIntron (peginterferon alfa-2b; SCH 54031)
- **DRUG:** REBETOL (ribavirin; SCH 18908)
- **BIOLOGICAL:** PEGASYS (peginterferon alfa-2a)
- **DRUG:** COPEGUS (ribavirin)

## Key facts

- **NCT ID:** NCT00081770
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 4469 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081770, "Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00081770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*